Literature DB >> 21947061

A prospective cohort study of light transmission platelet aggregometry for bleeding disorders: is testing native platelet-rich plasma non-inferior to testing platelet count adjusted samples?

Jean Francois Castilloux1, Karen A Moffat, Yang Liu, Jodi Seecharan, Menaka Pai, Catherine P M Hayward.   

Abstract

Light transmission platelet aggregometry (LTA) is important to diagnose bleeding disorders. Experts recommend testing LTA with native (N) rather than platelet count adjusted (A) platelet-rich plasma (PRP), although it is unclear if this provides non-inferior, or superior, detection of bleeding disorders. Our goal was to determine if LTA with NPRP is non-inferior to LTA with APRP for bleeding disorder assessments. A prospective cohort of patients, referred for bleeding disorder testing, and healthy controls, were evaluated by LTA using common agonists, NPRP and APRP (adjusted to 250 x 10⁹ platelets/l). Recruitment continued until 40 controls and 40 patients with definite bleeding disorders were tested. Maximal aggregation (MA) data were assessed for the detection of abnormalities from bleeding disorders (all causes combined to limit bias), using sample-type specific reference intervals. Areas under receiver-operator curves (AUROC) were evaluated using pre-defined criteria (area differences: < 0.15 for non-inferiority, > 0 for superiority). Forty-four controls and 209 patients were evaluated. Chart reviews for 169 patients indicated 67 had bleeding disorders, 28 from inherited platelet secretion defects. Mean MA differences between NPRP and APRP were small for most agonists (ranges, controls: -3.3 to 5.8; patients: -3.0 to 13.7). With both samples, reduced MA with two or more agonists was associated with a bleeding disorder. AUROC differences between NPRP and APRP were small and indicated that NPRP were non-inferior to APRP for detecting bleeding disorders by LTA, whereas APRP met superiority criteria. Our study validates using either NPRP or APRP for LTA assessments of bleeding disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947061     DOI: 10.1160/TH11-06-0378

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Bio-modulators in platelet-rich plasma: a comparison of the amounts in products from healthy donors and patients produced with three different techniques.

Authors:  Gianluca Ubezio; Massimo Ghio; Paola Contini; Roberta Bertorello; Gennaro Marino; Andrea Tomasini; Gino Tripodi
Journal:  Blood Transfus       Date:  2013-01-23       Impact factor: 3.443

2.  Bleeding risks for uncharacterized platelet function disorders.

Authors:  Justin Brunet; Matthew Badin; Michael Chong; Janaki Iyer; Subia Tasneem; Lucas Graf; Georges E Rivard; Andrew D Paterson; Guillaume Pare; Catherine P M Hayward
Journal:  Res Pract Thromb Haemost       Date:  2020-05-30

3.  Platelet lumiaggregation testing: Reference intervals and the effect of acetylsalicylic acid in healthy adults.

Authors:  Alenka Trampuš-Bakija; Janez Jazbec; Barbara Faganel-Kotnik
Journal:  J Med Biochem       Date:  2020-10-02       Impact factor: 3.402

4.  High Prevalence of Sticky Platelet Syndrome in Patients with Infertility and Pregnancy Loss.

Authors:  Eray Yagmur; Eva Bast; Anja Susanne Mühlfeld; Alexander Koch; Ralf Weiskirchen; Frank Tacke; Joseph Neulen
Journal:  J Clin Med       Date:  2019-08-28       Impact factor: 4.241

5.  A multicenter study to evaluate automated platelet aggregometry on Sysmex CS-series coagulation analyzers-preliminary findings.

Authors:  Sean Platton; Áine McCormick; Musfira Bukht; David Gurney; Ian Holding; Gary W Moore
Journal:  Res Pract Thromb Haemost       Date:  2018-08-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.